Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-Label Trial of MOv18 IgE in Patients With Solid Tumours That Overexpress Folate Receptor Alpha

NCT06547840 is registered in ClinicalTrials.gov with Epsilogen Ltd as lead sponsor.

NCT NCT06547840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06547840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-Label Trial of MOv18 IgE in Patients With Solid Tumours That Overexpress Folate Receptor Alpha
Lead sponsor
Epsilogen Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
September 3, 2024
Completion date
March 31, 2027
Enrollment
45 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced endometrial cancer, advanced ovarian cancer, endometrial cancer, platinum-resistant ovarian cancer, triple -negative breast cancer, triple negative breast cancer (tnbc)